Literature DB >> 35245448

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma.

Shun Yamamoto1, Ken Kato2.   

Abstract

The phase III JUPITER-6 trial showed superior progression-free survival and overall survival for toripalimab plus chemotherapy, compared with chemotherapy alone, in previously untreated patients with advanced esophageal squamous cell carcinoma. This provides solid evidence that immune checkpoint inhibitors are key drugs for the first-line treatment of advanced esophageal squamous cell carcinoma.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35245448     DOI： 10.1016/j.ccell.2022.02.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  2 in total

1.  First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis.

Authors:  Xueqiong Cao; Hongfu Cai; Na Li; Bin Zheng; Zhiwei Zheng; Maobai Liu
Journal:  Ther Adv Med Oncol       Date:  2022-09-16       Impact factor: 5.485

2.  The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy.

Authors:  Richard P T Evans; Hayden Pearce; Ewen A Griffiths; Paul Moss; Wayne Croft; Mona Elshafie
Journal:  Mol Cancer       Date:  2022-10-17       Impact factor: 41.444
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.